Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature.
about
Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancerSecond or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced diseaseChemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancerSecond or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced diseaseClinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic reviewThe role of mitomycin in the treatment of non-small cell lung cancer: a systematic review with meta-analysis of the literatureCeritinib: A primer for pharmacists.Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II studyPhase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer.A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma.Phase I/II study of cisplatin combined with weekly paclitaxel in patients with advanced non-small-cell lung cancer.Measurement and impact of co-morbidity in elderly patients with advanced non-small cell lung cancer treated with chemotherapy. A phase II study of weekly paclitaxel.Combination of gemcitabine and cisplatin as first-line therapy in advanced non-small-cell lung cancerComparison of vinorelbine-Cisplatin with gemcitabine-Cisplatin in patients with advanced non-small cell lung cancer.Triplet chemotherapy combination with cisplatin, gemcitabine and docetaxel in patients with chemotherapy-naive advanced non-small cell lung cancer.PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-sThe Cancer Communication Assessment Tool for Patients and Families (CCAT-PF): a new measure.Differential patient-caregiver opinions of treatment and care for advanced lung cancer patients.U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews.Second-line chemotherapy for non-small cell lung cancer.Triplet chemotherapy with vinorelbine, gemcitabine, and cisplatin for advanced non-small cell lung cancer: a phase II studyAdvanced non-small cell lung cancer: the role of maintenance therapyPreclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of originPhase I Study of Oral Vinorelbine in Combination with Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Using Two Different Schedules.Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer.Enhancing treatment decision-making: pilot study of a treatment decision aid in stage IV non-small cell lung cancer.Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer.Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis.Non-small-cell lung cancer: treatment of late stage disease: chemotherapeutics and new frontiers.Variations in Oncologist Recommendations for Chemotherapy for Stage IV Lung Cancer: What Is the Role of Performance Status?Comparison of bevacizumab plus chemotherapy with chemotherapy alone in advanced non-small-lung cancer patientsOutcomes of patients with unresected stage III and stage IV non-small cell lung cancer: A single institution experience.Randomized, multi-center phase II trial of docetaxel plus cisplatin versus etoposide plus cisplatin as the first-line therapy for patients with advanced non-small cell lung cancer.Effect of chemotherapy on quality of life in patients with non-small cell lung cancer.P53 expression, DNA ploidy and S-phase cell fraction in operable locally advanced non-small-cell lung cancerClinical studies in non-small cell lung cancer: the CALGB experience.Palliative chemotherapy.A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer.Trends in the pattern of care for lung cancer and their correlation with new clinical evidence: experiences in a university-affiliated medical center.
P2860
Q24187972-AB344DDA-C647-44C4-8B45-1AF4FBD90152Q24200518-E1311304-3F87-49F4-A5B1-FC82F72EF417Q24202281-8026162A-AA79-4D8C-9895-3CE8F598739FQ24243664-7FF776D8-DDC0-403B-985E-20CC84052E15Q24678961-0DE772C7-A1B4-4277-8CA5-5A3DE20305B3Q28364191-34D95702-112E-4976-AC0D-E55EBC6CF4AEQ30244613-8A965044-7033-4F24-A51F-176D7AFE1705Q33331901-2F74D3BB-9148-4808-B924-E17D98C0A0FAQ33334597-21DC000A-0F17-4BC5-B6A1-4BFE3A57818EQ33344553-BD20BED8-F781-412A-A915-94E2BA67E054Q33360013-02368C3B-EA1B-419E-A27C-BB3996CF6B01Q33374962-2B694517-97BE-43F4-BE64-EC4E9320BC24Q33389157-4261D05A-864F-4AE5-A819-2830D7F7C93AQ33393287-59AC98F2-276E-424F-974C-BB542E6C1C8FQ33408330-1F8E04DE-6D00-4AB5-86A2-568D0FB9B48BQ33418542-DEAC0862-6BCF-45C7-83FE-6135BD0DBB9EQ33694671-40B091B2-C237-4EF2-BD13-2562909A6D5CQ33733275-581ED0AF-28C1-4B4B-8DC5-F8ABEB2092C8Q33829794-9283334D-85FF-4DFA-A67E-C57F785B6172Q33837105-7D19FCD1-5C73-4321-BB00-D2AFD0F9FFF7Q34424790-CD5BD359-A87C-4236-90F4-636C934E34A0Q35010260-DCCD9B76-24D2-417F-A75E-D2F9C2EDE460Q35076224-07F0B3E9-8F50-4694-BCF1-4B4009D475FBQ35179487-DA2B5421-FD58-4CA3-A93E-9FDEB8EDB3B5Q36005030-87D6B2DC-D0F4-425E-ADDD-FDD0CB52F777Q36612331-3322EA53-8C35-4F33-A864-9D7EA7FA0BDDQ36696458-CDE755F2-063B-4BBB-90B4-6C970846DA4CQ36772562-205F1499-6DA5-404D-AA41-D36B2795B40FQ36871717-FFB33618-D3FC-485D-A58F-AD80EBCCED33Q37008086-E851C660-1674-403B-A922-7C57145891E9Q37117859-39A14F2E-27E6-4F5D-B938-E8D2966C92FFQ37152528-CD95D9EF-264D-464B-B075-754A7F1360B9Q37177238-B69AFBBF-86C0-4D1B-A1EC-21F4C564C129Q37449257-259E8674-B94E-4B37-891F-D91B30568223Q38190461-5025DB9A-97EB-4162-8EFD-F24D096B21EAQ39989754-8D802BFE-7DFF-4B43-AAA7-F919ADD0848DQ40865998-89F5A8E5-9112-42FF-99A1-4D7BDBBF2AF2Q41739152-3905E7E4-B63A-4B08-AEF4-4E6DC5CD66BBQ43260541-DB6B20B8-1E02-4ED1-8654-34C93F45ED9EQ43521521-2DDD0F6D-B635-49F9-B4B2-7F279D09E4CA
P2860
Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature.
description
1994 nî lūn-bûn
@nan
1994 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Chemotherapy vs supportive car ...... ta-analysis of the literature.
@ast
Chemotherapy vs supportive car ...... ta-analysis of the literature.
@en
Chemotherapy vs supportive car ...... ta-analysis of the literature.
@nl
type
label
Chemotherapy vs supportive car ...... ta-analysis of the literature.
@ast
Chemotherapy vs supportive car ...... ta-analysis of the literature.
@en
Chemotherapy vs supportive car ...... ta-analysis of the literature.
@nl
prefLabel
Chemotherapy vs supportive car ...... ta-analysis of the literature.
@ast
Chemotherapy vs supportive car ...... ta-analysis of the literature.
@en
Chemotherapy vs supportive car ...... ta-analysis of the literature.
@nl
P2093
P356
P1433
P1476
Chemotherapy vs supportive car ...... ta-analysis of the literature.
@en
P2093
Invernizzi F
Pampallona S
Preatoni A
P304
P356
10.1378/CHEST.106.3.861
P407
P577
1994-09-01T00:00:00Z